ALK Amplification and Crizotinib Sensitivity in Non-Small Cell Lung Cancer Cell Lines and Patients Report.

Kalai Khadija,Nathalie Auger,Beranger Lueza,Frederic Commo,Alexander Valent,Vanessa Rousseau,Nicolas Dorvault,Luc Friboulet,Ken Olaussen, Laetitia Rajpar,David Planchard,Ludovic Lacroix,Jean-Pierre Pignon,Jean-Charles Soria,Benjamin Besse

Journal of clinical oncology（2012）

引用 25|浏览52

暂无评分

摘要

10556 Background: ALK high copy number (HCN) seems to be a frequent event, described in 13-17% of Non-small cell lung cancer (NSCLC). The goal of this study was to describe ALK genomic aberrations ...

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要